// App-Quantinova.ai

9059 : A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.

Researchers

Presenter

  • Giorgio V. Scagliotti

Principal Investigators

  • Igor Bondarenko

  • Tudor-Eliade Ciuleanu

  • Maciej Bryl

  • Andrea Fulop

  • David Vicente

  • Helge Bischoff

  • Karla Hurt

  • Yi Lu

  • Shawn Estrem

  • Sameera R. Wijayawardana

  • Alan Chiang

  • Ramaswamy Govindan

Medical Centers

  • Department of Hematology, University of Torino, Torino, Italy

  • Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine

  • Institute of Oncology/University of Medicine and Pharmacy, Cluj-Napoca, Romania

  • E.J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Poznan, Poland

  • Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary, Budapest, Hungary

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Thoraxklinik, Heidelberg, Germany

  • Eli Lilly and Company, Indianapolis, IN

  • Washington University School of Medicine, St. Louis, MO

Locations

  • Italy

  • Poland

  • Spain

  • Germany

  • United States

  • Ukraine

  • Romania

  • Hungary

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Abemaciclib

  • Docetaxel

Outcome

  • Negative

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02450539

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved